EZR and chronic obstructive pulmonary disease: Thus, Ezrin, AKAP95, and Yotiao may represent future therapeutic targets for inhibiting bronchial EMT in COPD, possibly in combination with already existing therapies, such as β2-agonists and PDE4 inhibitors.